Immunocore Holdings PLC (IMCR)
59.90
+0.05
(+0.08%)
USD |
NASDAQ |
May 10, 09:49
Immunocore Holdings Profit Margin (Quarterly): -25.01% for Dec. 31, 2023
Profit Margin (Quarterly) Chart
Historical Profit Margin (Quarterly) Data
| Date | Value |
|---|---|
| December 31, 2023 | -25.01% |
| September 30, 2023 | 3.70% |
| June 30, 2023 | -29.47% |
| March 31, 2023 | -37.49% |
| December 31, 2022 | -46.41% |
| September 30, 2022 | 15.12% |
| June 30, 2022 | -19.13% |
| March 31, 2022 | -71.76% |
| December 31, 2021 | -530.9% |
| Date | Value |
|---|---|
| September 30, 2021 | -508.7% |
| June 30, 2021 | -575.0% |
| March 31, 2021 | -351.1% |
| December 31, 2020 | -254.4% |
| September 30, 2020 | -291.0% |
| June 30, 2020 | -221.1% |
| March 31, 2020 | -225.8% |
| December 31, 2019 | -460.2% |
Profit Margin Definition
Profit Margin is calculated using Net Income/Revenue. This metric measures the overall efficiency of a company in being able to turn revenue into profit. An analyst looking at profit margin might look for a higher profit margin relative to other comparable companies as well as a profit margin that is growing.
Profit Margin (Quarterly) Range, Past 5 Years
-575.0%
Minimum
Jun 2021
15.12%
Maximum
Sep 2022
-213.4%
Average
-221.1%
Median
Jun 2020
Profit Margin (Quarterly) Benchmarks
| Bicycle Therapeutics PLC | -136.0% |
| Adaptimmune Therapeutics PLC | -20.74K% |
| Biodexa Pharmaceuticals Plc | -- |
| Verona Pharma PLC | -- |
| NuCana PLC | -- |
Profit Margin (Quarterly) Related Metrics
| Return on Equity | -17.74% |
| Return on Assets | -11.19% |
| Return on Invested Capital | -15.61% |
| Operating Margin (Quarterly) | -24.52% |
| Return on Net Operating Assets | -57.25% |